All Submitted Clinical Trials

Clinical Trials > All Submitted Clinical Trials

It is not the intention of the Cholangiocarcinoma Foundation to provide specific medical advice.  We provide website users with information to help them better understand their health conditions and the current approaches related to prevention, diagnosis, treatment and supportive care. You are urged to always seek the advice of your physician or other qualified healthcare provider.

Now Enrolling

A Study of TAS-120 in Patients With Advanced Solid Tumors

This is an open-label, nonrandomized, Phase 1 dose-escalation, dose-expansion, and Phase 2 study targeting tumors with FGF/FGFR aberrations. The purpose of the study is to evaluate the safety, tolerability, PK, pharmacodynamic, and anti-tumor activity of TAS-120 in patients with advanced solid tumors with and without FGF/FGFR-related abnormalities.

read more

Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

Study Name Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations ClinicalTrials.gov Identifier (if applicable) NCT01948297 Clinical Trial Category (check all that apply) Beyond First Line Therapy Targeted Therapy Study Center Institution Name The University of Texas MD Anderson Cancer Center Institution Address 1515 Holcombe Blvd City Houston State Texas Zip Code 77030 Phone (713) 745-0746 Website http://www.mdanderson.org List additional Institutions (include address, phone number, and website) Dana-Farber Cancer Institute – Boston, Massachusetts, United States Massachusetts General Hospital – Boston, Massachusetts, United States Memorial Sloan-Kettering Hospital – New York, New York, United States Seoul National University Hospital – Seoul, Republic of Korea National Cancer Center Singapore – Singapore, Singapore Vall d’Hebron University Hospital – Barcelona, Spain Taipei... read more

DeLiver-FGFR: A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

FGFR2 genetic alterations (changes) are associated with different types of cancer. A drug that inhibits the activity of FGFR2 may be beneficial for the treatment of these cancers. In a recent trial, patients with intrahepatic cholangiocarcinoma with a genetic alteration known as “FGFR2 gene fusion”, benefited the most from treatment with ARQ 087.

read more

Translate »

Pin It on Pinterest